PE20080141A1 - Sistemas estables de nanocapsulas para la administracion de moleculas activas - Google Patents

Sistemas estables de nanocapsulas para la administracion de moleculas activas

Info

Publication number
PE20080141A1
PE20080141A1 PE2007000261A PE2007000261A PE20080141A1 PE 20080141 A1 PE20080141 A1 PE 20080141A1 PE 2007000261 A PE2007000261 A PE 2007000261A PE 2007000261 A PE2007000261 A PE 2007000261A PE 20080141 A1 PE20080141 A1 PE 20080141A1
Authority
PE
Peru
Prior art keywords
molecula
active
lipofilica
refers
oil
Prior art date
Application number
PE2007000261A
Other languages
English (en)
Inventor
Pena Ana Isabel Vila
Luque Silvia Suarez
Fernandez Maria Jose Alonso
Original Assignee
Advanced In Vitro Cell Technologies S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced In Vitro Cell Technologies S L filed Critical Advanced In Vitro Cell Technologies S L
Publication of PE20080141A1 publication Critical patent/PE20080141A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN SISTEMA DE NANOCAPSULAS CON UN TAMANO INFERIOR 1 UM DISPERSAS EN UN MEDIO ACUOSO, DONDE LA NANOCAPSULA COMPRENDE A) UNA FASE LIPOFILICA QUE COMPRENDE: i) AL MENOS UN COMPONENTE FOSFOLIPIDICO TAL COMO LECITINA DE SOJA; ii) UN ACEITE QUE COMPRENDE UNO O MAS ACIDOS GRASOS DE CADENA (C12-C24) SATURADOS Y/O INSATURADOS TAL COMO ACEITE DE RICINO; Y B) UNA FASE HIDROFILICA QUE COMPRENDE: i) QUITOSANO O UN DERIVADO; Y ii) UN COMPUESTO POLIOXIALQUILENADO TAL COMO POLIOXIETILENO O UN COPOLIMERO DE OXIDO DE ETILENO-OXIDO DE PROPILENO; ADEMAS COMPRENDE UNA MOLECULA LIPOFILICA ACTIVA EN LA FASE LIPOFILA SELECCIONADO DE CICLOSPORINA, HODROCORTISONA, PREDNISONA, ENTRE OTRAS; O UNA M0LECULA ACTIVA DE CARACTER HIDROLIFICO ADSORBIDA SOBRE LA SUPERFICIE DE LA NANOPCAPSULA SELECCIONADO DE PEPTIDOS PROTEINAS, HORMONAS, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA O COSMETICA CUANDO COMPRENDE UNA MOLECULA LIPOFILICA COSMETICA TAL COMO EMOLIENTE, CONSERVANTE, ENTRE OTRAS. ESTE SISTEMA PRESENTA UNA ELEVADA ESTABILIDAD DURANTE LARGOS PERIODOS Y CAPACIDAD PARA SER SOMETIDOS A ALTAS TEMPERATURAS
PE2007000261A 2006-03-13 2007-03-09 Sistemas estables de nanocapsulas para la administracion de moleculas activas PE20080141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06380048A EP1834635B1 (en) 2006-03-13 2006-03-13 Stable nanocapsule systems for the administration of active molecules

Publications (1)

Publication Number Publication Date
PE20080141A1 true PE20080141A1 (es) 2008-03-04

Family

ID=36743270

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000261A PE20080141A1 (es) 2006-03-13 2007-03-09 Sistemas estables de nanocapsulas para la administracion de moleculas activas

Country Status (17)

Country Link
US (1) US20090074824A1 (es)
EP (1) EP1834635B1 (es)
JP (1) JP5222739B2 (es)
KR (1) KR20080102303A (es)
CN (1) CN101426479B (es)
AR (1) AR059829A1 (es)
AT (1) ATE515260T1 (es)
AU (1) AU2007224471B2 (es)
BR (1) BRPI0709594A2 (es)
CA (1) CA2646338A1 (es)
DK (1) DK1834635T3 (es)
ES (1) ES2369244T3 (es)
IL (1) IL194005A0 (es)
PE (1) PE20080141A1 (es)
PL (1) PL1834635T3 (es)
PT (1) PT1834635E (es)
WO (1) WO2007104732A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119780B2 (en) 2006-06-02 2012-02-21 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
KR20100062990A (ko) * 2007-06-12 2010-06-10 크리스틴 알렌 국소적 약물전달을 위한 주사용 고분자-지질 배합물
EP2042166A1 (en) * 2007-09-25 2009-04-01 The Jordanian Pharmaceutical Manufacturing Co. Nanocapsules for oral delivery of proteins
SI2200588T1 (sl) * 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
KR101199580B1 (ko) * 2008-08-06 2013-11-27 (주)에델프라우 국소 투여용 나노에멀젼
BRPI0805854A2 (pt) 2008-10-10 2010-08-24 Biolab Sanus Farmaceutica Ltda sistema nanoparticulado, processo de preparaÇço do mesmo, uso do mesmo, composiÇço fotoproterora, processo de preparaÇço da mesma, mÉtodo de prevenÇço de doenÇas e distérbios da pele
TWI328565B (en) * 2008-12-19 2010-08-11 Taiwan Textile Res Inst Dispersions of conductive carbon materials and methods for preparing the same
EP2405934B1 (en) 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
EP2266546A1 (en) * 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
EP2364600A1 (en) * 2010-02-18 2011-09-14 Nestec S.A. Liquid-filled chitosan-anionic liposoluble capsule dispsersions
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
JP6189749B2 (ja) * 2010-06-23 2017-08-30 ブライトサイド イノベーションズ，インコーポレイティド レシチン担体小胞とその作製方法
EP2642985A4 (en) * 2010-11-26 2014-05-07 Univ Witwatersrand Jhb POLYMER MATRIX OF POLYMER-LIPID NANOPARTICLES AS DOSED PHARMACEUTICAL FORM
US9801829B2 (en) * 2011-04-29 2017-10-31 University Of Florida Research Foundation, Inc. Methods and systems of making nanostructures
DE102011076149A1 (de) * 2011-05-19 2012-11-22 Rovi Cosmetics International Gmbh Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare
ES2366255B2 (es) * 2011-06-27 2012-08-08 Universidade De Santiago De Compostela Nanocomposiciones sacarídicas para la liberación de vacunas.
JP6170933B2 (ja) 2011-11-02 2017-07-26 キーバイオサイエンス・アクチエンゲゼルシャフト ペプチドの使用
HUE039105T2 (hu) 2011-11-02 2018-12-28 Keybioscience Ag Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
US20130123194A1 (en) * 2011-11-15 2013-05-16 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
US8968790B2 (en) 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
EP2625966A1 (en) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof
WO2014096165A2 (en) * 2012-12-21 2014-06-26 Bracco Suisse Sa Gas-filled microvesicles
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
DK3068796T3 (en) 2013-11-14 2018-03-05 Keybioscience Ag CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
CN104117066B (zh) 2014-07-16 2016-03-02 陈凌 外敷用抗甲状腺软膏的制备方法
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
CA2979184C (en) 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
PL229276B1 (pl) * 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
TWI709410B (zh) * 2015-08-11 2020-11-11 荷蘭商艾西優藥物股份有限公司 具有生物活性親脂性化合物之聚乙二醇化脂質奈米粒子
JP2019513359A (ja) * 2016-03-25 2019-05-30 アディッソ・フランス・エス．エー．エス．Ａｄｉｓｓｅｏ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． 脂溶性の有効成分のナノカプセル並びにその製造方法及び使用方法
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药***的组方与应用
EP4272731A3 (en) 2018-12-11 2024-02-14 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
DE59310166D1 (de) * 1992-05-18 2001-05-31 Ciclomulsion Ag Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
US20030224022A1 (en) * 1993-01-19 2003-12-04 Amos Nussinovitch Hydrocolloid cellular solid matrices
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
JP3441665B2 (ja) * 1999-02-04 2003-09-02 株式会社資生堂 （２−置換オキシフェニル）アルカンアミド誘導体及び養毛剤、皮膚外用剤
EP1190702A1 (en) * 2000-09-22 2002-03-27 Ciba SC Holding AG Chitosan emulsion formulation
EP1243323B1 (de) * 2001-03-22 2005-01-05 Cognis Iberia, S.L. Nanokapseln
JP2005513097A (ja) * 2001-11-01 2005-05-12 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム ドライアイ治療方法および組成物

Also Published As

Publication number Publication date
PT1834635E (pt) 2011-10-13
AU2007224471B2 (en) 2013-05-02
JP5222739B2 (ja) 2013-06-26
CN101426479B (zh) 2012-10-10
AR059829A1 (es) 2008-04-30
AU2007224471A1 (en) 2007-09-20
PL1834635T3 (pl) 2012-01-31
EP1834635A1 (en) 2007-09-19
ES2369244T3 (es) 2011-11-28
WO2007104732A3 (en) 2007-11-08
CN101426479A (zh) 2009-05-06
EP1834635B1 (en) 2011-07-06
DK1834635T3 (da) 2011-10-24
JP2009530241A (ja) 2009-08-27
ATE515260T1 (de) 2011-07-15
WO2007104732A2 (en) 2007-09-20
BRPI0709594A2 (pt) 2011-07-19
US20090074824A1 (en) 2009-03-19
CA2646338A1 (en) 2007-09-20
IL194005A0 (en) 2011-08-01
KR20080102303A (ko) 2008-11-24

Similar Documents

Publication Publication Date Title
PE20080141A1 (es) Sistemas estables de nanocapsulas para la administracion de moleculas activas
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
ES2482090T3 (es) Procedimiento de preparación de nano-emulsiones
BR112019004935A2 (pt) composições de toxina clostridial não proteíca estabilizada
WO2011153493A3 (en) Biodegradable lipids for the delivery of active agents
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ES2531173T3 (es) Vehículos de administración de microemulsiones de lecitina a base de enlazadores
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
MX2008009357A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
PE20050926A1 (es) Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension
EP3699172A3 (en) Novel lipids and compositions for the delivery of therapeutics
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
WO2007018943A3 (en) Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EA200800258A1 (ru) Эмульсионные композиции пропофола для внутривенного введения, имеющие консервирующую эффективность
AR059843A1 (es) Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
CL2013000715A1 (es) Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.
AR065861A1 (es) Formulaciones farmaceuticas basadas en lipidos apolares y polares para uso oftalmico
EP4218722A3 (en) Biodegradable lipids for the delivery of active agents
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
CO6280437A2 (es) Una composicion de emulsion de aceite en agua que tiene una fase de agua y nua fase de aceite comprendiendo un modificador polimerico y un compuesto activo agricolamente
CA2929865C (en) Sprayable topical carrier and composition comprising phosphatidylcholine
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
CR20110190A (es) Agente rodenticida sinérgico

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed